Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis

Andrea Casadei-Gardini, Alessandro Vagheggini, Fabio Gelsomino, Andrea Spallanzani, Paola Ulivi, Giulia Orsi, Giulia Rovesti, Kalliopi Andrikou, Emiliano Tamburini, Mario Scartozzi, Stefano Cascinu

Research output: Contribution to journalArticlepeer-review


In the absence of head-to-head comparison studies, the present network meta-analysis evaluated and compared the efficacy of 4 therapeutic alternatives for refractory colorectal cancer. No difference in overall survival was found between regorafenib and TAS-102. Possible greater efficacy with TAS-102 compared with regorafenib was found for patients with a rectal primary location, performance status > 0, and age > 65 years. Regorafenib showed possible greater effectiveness for patients with performance status of 0 and age < 65 years. In the RAS wild-type population, the anti-EGFR drug showed superiority to TAS-102 and regorafenib. These results are only exploratory, and further prospective studies are warranted to validate these data.

Original languageEnglish
Pages (from-to)82-90.e9
JournalClinical Colorectal Cancer
Issue number2
Publication statusPublished - Jun 2020


  • Anti-EGFR
  • Cetuximab
  • Metastatic colorectal cancer
  • Panitumumab
  • Regorafenib
  • TAS-102
  • Third-line therapy

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology


Dive into the research topics of 'Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis'. Together they form a unique fingerprint.

Cite this